Clinical Trials

400 enrolled

Carcinoma, Intraductal, Noninfiltrating

NCT06218303 2026-03-12

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

Phase 1 Recruiting

50 enrolled

Carcinoma, Intraductal, Noninfiltrating

NCT06671912 2026-03-04

LoTam

Phase 3 Suspended

1,156 enrolled

Breast Carcinoma In Situ

NCT04852887 2026-03-03

DEBRA

1,670 enrolled

Breast Neoplasms

NCT02767661 2026-02-27

MECCA

263 enrolled

Breast Neoplasms

NCT05467891 2026-02-27

RaPhLRR

200 enrolled

Locoregional Recurrence

NCT06179303 2026-02-27

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

60 enrolled

Anatomic Stage III Breast Cancer AJCC v8

NCT03179904 2026-02-24

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

17 enrolled 10 charts

Advanced Breast Carcinoma

NCT06507618 2026-02-24

POWER II

354 enrolled

Breast Neoplasms

NCT07019363 2026-01-21

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

1,903 enrolled

Breast Neoplasms

NCT06001762 2026-01-16

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

90 enrolled

Breast Neoplasms

NCT04584853 2026-01-14

POETIC-A

123 enrolled

Breast Cancer Female

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT05150652 2026-01-07

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

8 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07299890 2025-12-23

An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer

90 enrolled

Breast Neoplasms

NCT03079011 2025-11-18

PADA-1

1,017 enrolled

Breast Neoplasms

NCT06364267 2025-11-18

BabyTears

140 enrolled

Breast Neoplasms

NCT04569747 2025-11-13

ADEPT

375 enrolled

Breast Neoplasms

NCT07190443 2025-09-29

AURA

290 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07179939 2025-09-18

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

288 enrolled

Phase 1 Not yet recruiting

HER2-positive Breast Cancer

NCT07163481 2025-09-16

SoGreat

12 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT04134598 2025-08-29

EUROPA

926 enrolled

Breast Neoplasms

NCT04300790 2025-07-29

METALLICA

69 enrolled

BreastEndocrine

Breast Neoplasms, Hyperglycemia, Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

NCT02476786 2025-07-28

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

50 enrolled

Breast Neoplasms

NCT05635357 2025-07-28

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/Letrozole

Completed

16,989 enrolled

Breast Neoplasms

NCT00253422 2025-06-04

SoFEA

698 enrolled 19 charts

Breast Neoplasms

NCT05472792 2025-05-23

CAMERAN

90 enrolled

Breast Neoplasms

NCT03554044 2025-05-21

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

Phase 1 Completed

20 enrolled

Breast Neoplasms

NCT02040857 2025-04-29

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

162 enrolled 12 charts

Breast Neoplasms

NCT03219476 2025-04-29

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

37 enrolled 10 charts

Breast Neoplasms

NCT00265759 2025-04-23

Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer

622 enrolled 18 charts

Breast Neoplasms

NCT03691493 2025-02-17

ASPIRE

36 enrolled 17 charts

Breast Neoplasms

NCT04985266 2024-12-05

TRAK-ER

1,100 enrolled

ER+ Breast Cancer

NCT02028507 2024-09-25

PEARL

693 enrolled 40 charts

Breast Neoplasms

NCT02188745 2024-07-17

POLLY

19 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT02676986 2024-07-05

ARB

221 enrolled

Primary Breast Cancer ER+ve

NCT01594216 2024-06-12

Ruxolitinib in Estrogen Receptor Positive Breast Cancer

25 enrolled 8 charts

Estrogen-receptor Positive Invasive Metastatic Breast Cancer

NCT02344472 2024-06-04

Detect V / CHEVENDO (Chemo vs. Endo)

271 enrolled

Breast Neoplasms

NCT02918084 2024-05-08

GIM10-CONSENT

1,000 enrolled

Breast Neoplasms

NCT04129216 2024-05-07

The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer

30 enrolled 10 charts

Breast Neoplasms

NCT02648477 2024-03-19

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

30 enrolled 11 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05891093 2024-02-08

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

766 enrolled

Breast Neoplasms

NCT01814397 2024-02-07

Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients

Completed

50 enrolled 15 charts

Breast Neoplasms, Pain, Arthralgia

NCT04465097 2023-10-17

NeoTEE

30 enrolled

Breast Neoplasms

NCT01303679 2023-09-06

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

Phase 3 Terminated

117 enrolled

First Line Metastatic Breast Cancer

NCT02028364 2023-08-24

PEARL

55 enrolled

Breast Neoplasms

NCT03555877 2023-07-07

AMICA

56 enrolled

Breast Cancer Metastatic

NCT00128843 2023-03-06

Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients

103 enrolled

Breast Neoplasms

NCT02990845 2023-02-22

PEER

Phase 1/2 Terminated

16 enrolled